Additionally, although BCMA-targeted T-cell immunotherapies (CAR T-cell therapy and bispecific antibodies) have substantially improved survival of triple-class refractory MM patients, most patients eventually develop disease progression.3, 5 Frequent occurrence of BCMAlow/negative disease and presence of BCMA mutations at the time of progression following BCMA-directed therapy underscores the need to investigate alternative target antigens for T-cell immunotherapies.7, 12. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.